Skip to main content
SpringerLink
Log in

Paclitaxel in the management of ovarian cancer: what we know and what we have yet to learn

  • Editorial
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

The “Journal of Cancer Research and Clinical Oncology” publishes in loose succession “Editorials” and “Guest editorials” on current and/or controversial problems in experimental and clinical oncology. These contributions represent exclusively the personal opinion of the authors. The Editors

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Bookman MA, McGuire WP, Kilpatrick D, Keenan E, Johnson S, O'Dwyer P, Rowinsky E, Ozols RF (1995) Phase-I Gynecologic Oncology Group study of 3-H and 24-H paclitaxel with carboplatin as initial therapy for advanced epithelial ovarian cancer. Proc Am Soc Clin Oncol 14:271

    Google Scholar 

  • Connelly E, Markman M, Webster K, Kennedy A, Kulp B, Peterson G, Belinson J (1995) Three hour infusional taxol with cisplatin in patients with gynecological cancers. Proc Am Soc Clin Oncol 14:277

    Google Scholar 

  • Daly D (1992)Tree of life. Audubon. March/April: 76–85

    Google Scholar 

  • Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg GL (1992) Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10:1748–1753

    Google Scholar 

  • Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg MEL, Kerr I, Vermorken JB, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B, Canetta R (1994) European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654–2666

    Google Scholar 

  • Kavanagh JJ, Kudelka AP, Edwards CL, Freedman RS, Gibbs H, Gonzalez de Leon C, Canetta R, Harper KJ, Kopplin S, Mante R, Krakoff IH (1993) A randomized crossover trial of parenteral hydroxyurea vs high dose taxol in cisplatin/carboplatin resistant epithelial ovarian cancer. Proc Am Soc Clin Oncol 12:259

    Google Scholar 

  • Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg SM, Rothenberg M, Adamo DO, Davis P, Ognibene FP, Cunnion RE, Reed E (1994) Dose-intensive taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86:18–24

    Google Scholar 

  • Lopes NM, Adams EG, Pitts TW, Bhuyan BK (1993) Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235–242

    Google Scholar 

  • McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Davidson M for the Gynecologic Oncology Group (1995) Taxol and cisplatin improves outcome in advanced ovarian cancer as compared to cytoxan and cisplatin. Proc Am Soc Clin Oncol 14:275

    Google Scholar 

  • McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC (1989) Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273–279

    Google Scholar 

  • Ozols RF, Kilpatrick D, O'Dwyer P, Johnson S, Bookman MA, Walczak J, Rowinsky E, McGuire WP (1993) Phase I and pharmacokinetic study of taxol and carboplatin in previously untreated patients with advanced epithelial ovarian cancer: A pilot study of the Gynecologic Oncology Group. Proc Am Soc Clin Oncol 12:259

    Google Scholar 

  • Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332:1004–1014

    Google Scholar 

  • Rowinsky EK, Donehower RC, Jones RJ, Tucker RW (1988) Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 48:4093–4100

    Google Scholar 

  • Sculier J-P, Klastersky J (1995) Cisplatin plus taxol in non-small cell lung cancer: A dose finding trial. Can J Infect Dis 6 (suppl C):204 C

    Google Scholar 

  • Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett JR (1994) Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: A Gynecologic Oncology Group study. J Clin Oncol 12:1748–1753

    Google Scholar 

  • Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS, Christian MC, Canetta R, Onetto N, Hayn R, Arbuck SG (1993) Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 11:2405–2410

    Google Scholar 

  • Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Fojo An, Steinberg SM, Goldspiel BR, Herdt J, O'Shaughnessy J, Balis FM, Chabner BA (1994) Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion. J Clin Oncol 12:1621–1629

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cleveland Clinic Cancer Center, The Cleveland Clinic Foundation, 44195, Cleveland, Ohio, USA

    Maurie Markman

  2. the Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, 44195, Cleveland, Ohio, USA

    Maurie Markman

Authors
  1. Maurie Markman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Markman, M. Paclitaxel in the management of ovarian cancer: what we know and what we have yet to learn. J Cancer Res Clin Oncol 122, 71–73 (1996). https://doi.org/10.1007/BF01226263

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01226263

Search

Navigation